DAY ONE
7:50 am Morning Refreshments & Check In
8:50 am Chair’s Opening Remarks
Utilising Broader Mechanistic Strategies to Optimize GLP-1 Therapies & Overcome Limitations for More Durable Metabolic Health
9:00 am Optimizing GLP-1/GIP Dual Agonism for Enhanced Weight Loss & Metabolic Control to Deliver Superior Patient Outcome
Synopsis
- Leveraging co-agonist mechanisms for synergistic receptor activation to maximize therapeutic efficacy for profound and sustained weight reduction
- Characterizing differential receptor potency for tailored pharmacological profiles to improve tolerability for broader patient applicability
- Leveraging large-scale clinical evidence to demonstrate comprehensive metabolic benefits, which establishes new standards of care for transformative patient outcomes
10:00 am Unlocking GLP-1 Potential by Targeting Secondary Mechanisms for Sustainable Weight Loss and Health
Synopsis
- Targeting the PI3K/AKT pathway to leverage a novel mechanism to modulate insulin signaling to overcome GLP-1 resistance for more durable metabolic health
- Combining GLP-1 agonists with lipid signaling modulators to engage multiple metabolic pathways simultaneously, resulting in greater weight loss and improved glycemic control than with GLP-1 monotherapy
- Focusing on receptor cross-talk as a mechanistic strategy to optimize the downstream effects of GLP-1 activation to enhance the therapeutic response and improve patient outcomes by addressing underlying limitations
10:30 am Innovating GLP-1 Mono-Agonist Development for Refined Efficacy & Safety to Expand Patient Accessibility
Synopsis
- Enhancing peptide stability and half-life for reduced dosing frequency to improve patient convenience for greater adherence
- Minimizing gastrointestinal side effects for improved patient comfort to increase treatment acceptance for wider clinical adoption
- Exploring novel delivery technologies for alternative administration routes to broaden patient access for diverse therapeutic needs
11:00 am Speed Networking Session
Synopsis
Put a face to a name – this session is the perfect opportunity to get face-to-face time with key opinion leaders, leading biotech and pharmaceutical companies, and innovative researchers in obesity drug development. Establish meaningful connections with companies working on early-stage through to clinical stage weight loss therapies. Build upon these connections throughout the rest of the conference and gain individual insight beyond the papers and press releases into the pioneering research and therapeutic development
11:40 am Morning Break & Networking
Integrating Muscle-Preserving Therapies to Elevate Metabolic Health & Improve Body Composition in Obesity Care
12:00 pm Developing Enobosarm Using A SARM-Based Strategy for Muscle Preservation & Improved Body Composition
Synopsis
- Enobosarm’s SARM-based action has been shown to prevent the loss of lean muscle mass during caloric restriction, which results in a more favorable body composition and sustained metabolic health
- This targeted strategy demonstrates the unique result of preferential fat loss over muscle loss, which provides a higher quality of weight reduction compared to other obesity treatments
- The development of enobosarm successfully addresses the clinical challenge of muscle wasting, leading to the outcome of improved physical function and a reduction in sarcopenic obesity
12:30 pm Session Reserved for Curi Bio
12:40 pm Integrating Exercise Mimetics for Mimicking Physical Activity Benefits to Boost Metabolic Rate for Healthier Weight Loss
Synopsis
- Mimicking endurance training effects for improving mitochondrial function to enhance fat oxidation for sustained energy expenditure
- Activating muscle signaling pathways for increased glucose uptake to improve insulin sensitivity for better metabolic control
- Developing pharmacological agents for stimulating exercise-induced gene expression to boost caloric burn for passive weight management
1:10 pm Panel Discussion: Assessing Functional Readouts & Optimal Muscle-to-Fat Ratio to Redefine Success in Obesity Care to Improve Drug Performance
Synopsis
- Analyzing the critical need for functional readouts and clinically relevant endpoints beyond weight on a scale to accurately measure and demonstrate the benefits of muscle preservation in obesity treatment •
- Discussing the scientific and clinical consensus on how much muscle loss is too much, focusing on the optimal muscle-tofat ratio to guide therapeutic development and achieve superior metabolic health outcomes
- Evaluating how integrating muscle-preserving therapies into obesity treatment can redefine success, unlock a new paradigm for comprehensive patient wellbeing, and provide more durable outcomes than weight loss alone
1:40 pm Lunch
Evaluating Therapeutic Modalities to Refine Obesity Treatment Development Strategies & Accelerate Patient-Centric Innovation
2:40 pm Comparing Oral vs. Injectable Delivery for Patient Preference & Adherence to Broaden Treatment Accessibility for Greater Patient Choice
Synopsis
- Assessing patient convenience factors for ease of administration to improve treatment adherence for more consistent therapeutic effects
- Evaluating bioavailability and absorption profiles for consistent drug exposure to ensure predictable efficacy for reliable patient responses
- Considering cost-effectiveness and reimbursement for wider patient access to reduce financial barriers for broader population reach
3:10 pm Reprogramming Immunometabolism: Ofirnoflast & GLP-1 Synergy in the Next Generation of Obesity Therapies
Synopsis
- A Dual-Targeted Strategy: Combining the metabolic effects of GLP-1 receptor agonists with Ofirnoflast’s direct inhibition of the NEK7-NLRP3 inflammasome tackles both appetite regulation and the chronic inflammation that underlies obesity and insulin resistance
- Enhanced Weight Loss and Glycemic Control: Preclinical studies demonstrate true synergy between Ofirnoflast and semaglutide, yielding superior reductions in weight, inflammatory markers, and glycemic control compared to either agent alone
- Beyond Weight: Disease Modification and Organ Protection: This combination offers the potential not only to accelerate and deepen weight loss but to reverse adipose dysfunction, preserve beta-cell function, and mitigate inflammation-driven comorbidities like cardiovascular, renal, and liver disease
3:40 pm Optimizing Activin Pathway Inhibition for Obesity – DIO Mouse Ffficacy as Monotherapy and in Combination with GLP-1 Agonism
Synopsis
- Oral small molecule inhibitors of the Activin receptor type II (ACTRII) reduce fat mass and liver mass/fat while preserving muscle in DIO mice
- This activity is accompanied by an increase in energy expenditure, maintenance of fat loss even after discontinuation of GLP-1 agonist treatment, and correlates with downstream signaling pathway activity in various tissues
- In combination with GLP-1 agonist treatment, oral ACTRII inhibition significantly enhances fat loss while preserving liver and lean mass benefits
4:10 pm Chair’s Closing Remarks
4:20 pm Poster Session & Networking
Synopsis
Connect with peers on the West Coast in a relaxed atmosphere and continue to forge new and existing relationships while exploring the latest in obesity research and advancements with presentations showcasing early stage to clinical stage drug development research. To submit a poster, please contact info@hansonwade.com